Restless legs syndrome in Parkinson's disease: relationship with quality of life and medication
We aimed to disclose the relationship between restless leg syndrome (RLS) and antiparkinsonian treatment, and its effect on quality of life (QoL) in patients with Parkinson's disease (PD). Previous studies documented the prevalence of RLS among patients with PD to be higher than in the general...
Gespeichert in:
| Veröffentlicht in: | Bratislava Medical Journal 2022-01, Vol.123 (1), p.55-60 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 60 |
|---|---|
| container_issue | 1 |
| container_start_page | 55 |
| container_title | Bratislava Medical Journal |
| container_volume | 123 |
| creator | Minar, M Kosutzka, Z Danterova, K Gmitterova, K Straka, I Kusnirova, A Tosecka, R Juricek, R Kloc, M Wyman-Chick, K A Valkovic, P |
| description | We aimed to disclose the relationship between restless leg syndrome (RLS) and antiparkinsonian treatment, and its effect on quality of life (QoL) in patients with Parkinson's disease (PD).
Previous studies documented the prevalence of RLS among patients with PD to be higher than in the general population, but conclusions regarding the aetiology and impact were contradictory.
We examined 101 patients with idiopathic PD. All participants completed the five-dimension/five-level-EuroQoL questionnaire (EQ-5D-5L) and the International Restless-Legs-syndrome-study-group rating Scale (IRLS).
The prevalence of RLS was 22.77 %. There were no statistically significant differences in levodopa or dopamine agonists (DA) doses between RLS-positive and negative participants. However, the use of levodopa as the last night-time medication was connected with a higher risk of RLS (OR=2.049, p=0.041). There was significantly lower prevalence of RLS in patients after surgical treatment for PD (p=0.024). Participants with RLS were at a greater risk for sleep disturbances (OR=3.866, p=0.023) and excessive daytime sleepiness (OR=7.202, p |
| doi_str_mv | 10.4149/BLL_2022_009 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2615477758</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2615477758</sourcerecordid><originalsourceid>FETCH-LOGICAL-c329t-d6ba78cdb67c0ac4945d92473a41325c16ffb05e6aa831da8e997b9e1780805a3</originalsourceid><addsrcrecordid>eNpNkDtPwzAYRS0EoqWwMSNvMBCw41fMBhUvKRIIwWw5sUMNTtLmS4T67wlQENNdjq7uPQgdUnLGKdfnV3luUpKmhhC9haaUMZkQxsU2mhJCZKJTnk3QHsAbIZwJKnfRhHEtlRR6isyThz56ABz9K2BYN65ra49Dgx9t9x4aaJtjwC6At-AvcOej7UPbwCIs8UfoF3g12Bj6NW4rHEPlsW0crr0L5Te3j3YqG8EfbHKGXm6un-d3Sf5wez-_zJOSpbpPnCysykpXSFUSW3LNhRuHK2Y5Zakoqayqgggvrc0YdTbzWqtCe6oykhFh2Qyd_PQuu3Y1jJ9MHaD0MdrGtwOYVFLBlVIiG9HTH7TsWoDOV2bZhdp2a0OJ-VJq_isd8aNN81CMv_7gX4fsE0Z9cm8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2615477758</pqid></control><display><type>article</type><title>Restless legs syndrome in Parkinson's disease: relationship with quality of life and medication</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Minar, M ; Kosutzka, Z ; Danterova, K ; Gmitterova, K ; Straka, I ; Kusnirova, A ; Tosecka, R ; Juricek, R ; Kloc, M ; Wyman-Chick, K A ; Valkovic, P</creator><creatorcontrib>Minar, M ; Kosutzka, Z ; Danterova, K ; Gmitterova, K ; Straka, I ; Kusnirova, A ; Tosecka, R ; Juricek, R ; Kloc, M ; Wyman-Chick, K A ; Valkovic, P</creatorcontrib><description>We aimed to disclose the relationship between restless leg syndrome (RLS) and antiparkinsonian treatment, and its effect on quality of life (QoL) in patients with Parkinson's disease (PD).
Previous studies documented the prevalence of RLS among patients with PD to be higher than in the general population, but conclusions regarding the aetiology and impact were contradictory.
We examined 101 patients with idiopathic PD. All participants completed the five-dimension/five-level-EuroQoL questionnaire (EQ-5D-5L) and the International Restless-Legs-syndrome-study-group rating Scale (IRLS).
The prevalence of RLS was 22.77 %. There were no statistically significant differences in levodopa or dopamine agonists (DA) doses between RLS-positive and negative participants. However, the use of levodopa as the last night-time medication was connected with a higher risk of RLS (OR=2.049, p=0.041). There was significantly lower prevalence of RLS in patients after surgical treatment for PD (p=0.024). Participants with RLS were at a greater risk for sleep disturbances (OR=3.866, p=0.023) and excessive daytime sleepiness (OR=7.202, p<0.001). Greater RLS symptoms were associated with worse QoL (higher IRLS score predicted higher EQ5D5L score, p=0.023).
RLS is prevalent among PD patients and night-time dopaminergic over-excitation with levodopa plays an important role in its pathogenesis. Since the symptoms of RLS are associated with decreased QoL, early accurate diagnosis and appropriate adjustment of dopaminergic therapy can lead to immediate relief from RLS symptoms and to QoL improvement (Tab. 4, Fig. 1, Ref. 34).</description><identifier>ISSN: 0006-9248</identifier><identifier>ISSN: 1336-0345</identifier><identifier>EISSN: 1336-0345</identifier><identifier>DOI: 10.4149/BLL_2022_009</identifier><identifier>PMID: 34967659</identifier><language>eng</language><publisher>Slovakia</publisher><subject>Dopamine Agonists - adverse effects ; Humans ; Parkinson Disease - complications ; Parkinson Disease - drug therapy ; Parkinson Disease - epidemiology ; Quality of Life ; Restless Legs Syndrome - drug therapy ; Restless Legs Syndrome - epidemiology ; Surveys and Questionnaires</subject><ispartof>Bratislava Medical Journal, 2022-01, Vol.123 (1), p.55-60</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c329t-d6ba78cdb67c0ac4945d92473a41325c16ffb05e6aa831da8e997b9e1780805a3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34967659$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Minar, M</creatorcontrib><creatorcontrib>Kosutzka, Z</creatorcontrib><creatorcontrib>Danterova, K</creatorcontrib><creatorcontrib>Gmitterova, K</creatorcontrib><creatorcontrib>Straka, I</creatorcontrib><creatorcontrib>Kusnirova, A</creatorcontrib><creatorcontrib>Tosecka, R</creatorcontrib><creatorcontrib>Juricek, R</creatorcontrib><creatorcontrib>Kloc, M</creatorcontrib><creatorcontrib>Wyman-Chick, K A</creatorcontrib><creatorcontrib>Valkovic, P</creatorcontrib><title>Restless legs syndrome in Parkinson's disease: relationship with quality of life and medication</title><title>Bratislava Medical Journal</title><addtitle>Bratisl Lek Listy</addtitle><description>We aimed to disclose the relationship between restless leg syndrome (RLS) and antiparkinsonian treatment, and its effect on quality of life (QoL) in patients with Parkinson's disease (PD).
Previous studies documented the prevalence of RLS among patients with PD to be higher than in the general population, but conclusions regarding the aetiology and impact were contradictory.
We examined 101 patients with idiopathic PD. All participants completed the five-dimension/five-level-EuroQoL questionnaire (EQ-5D-5L) and the International Restless-Legs-syndrome-study-group rating Scale (IRLS).
The prevalence of RLS was 22.77 %. There were no statistically significant differences in levodopa or dopamine agonists (DA) doses between RLS-positive and negative participants. However, the use of levodopa as the last night-time medication was connected with a higher risk of RLS (OR=2.049, p=0.041). There was significantly lower prevalence of RLS in patients after surgical treatment for PD (p=0.024). Participants with RLS were at a greater risk for sleep disturbances (OR=3.866, p=0.023) and excessive daytime sleepiness (OR=7.202, p<0.001). Greater RLS symptoms were associated with worse QoL (higher IRLS score predicted higher EQ5D5L score, p=0.023).
RLS is prevalent among PD patients and night-time dopaminergic over-excitation with levodopa plays an important role in its pathogenesis. Since the symptoms of RLS are associated with decreased QoL, early accurate diagnosis and appropriate adjustment of dopaminergic therapy can lead to immediate relief from RLS symptoms and to QoL improvement (Tab. 4, Fig. 1, Ref. 34).</description><subject>Dopamine Agonists - adverse effects</subject><subject>Humans</subject><subject>Parkinson Disease - complications</subject><subject>Parkinson Disease - drug therapy</subject><subject>Parkinson Disease - epidemiology</subject><subject>Quality of Life</subject><subject>Restless Legs Syndrome - drug therapy</subject><subject>Restless Legs Syndrome - epidemiology</subject><subject>Surveys and Questionnaires</subject><issn>0006-9248</issn><issn>1336-0345</issn><issn>1336-0345</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkDtPwzAYRS0EoqWwMSNvMBCw41fMBhUvKRIIwWw5sUMNTtLmS4T67wlQENNdjq7uPQgdUnLGKdfnV3luUpKmhhC9haaUMZkQxsU2mhJCZKJTnk3QHsAbIZwJKnfRhHEtlRR6isyThz56ABz9K2BYN65ra49Dgx9t9x4aaJtjwC6At-AvcOej7UPbwCIs8UfoF3g12Bj6NW4rHEPlsW0crr0L5Te3j3YqG8EfbHKGXm6un-d3Sf5wez-_zJOSpbpPnCysykpXSFUSW3LNhRuHK2Y5Zakoqayqgggvrc0YdTbzWqtCe6oykhFh2Qyd_PQuu3Y1jJ9MHaD0MdrGtwOYVFLBlVIiG9HTH7TsWoDOV2bZhdp2a0OJ-VJq_isd8aNN81CMv_7gX4fsE0Z9cm8</recordid><startdate>20220101</startdate><enddate>20220101</enddate><creator>Minar, M</creator><creator>Kosutzka, Z</creator><creator>Danterova, K</creator><creator>Gmitterova, K</creator><creator>Straka, I</creator><creator>Kusnirova, A</creator><creator>Tosecka, R</creator><creator>Juricek, R</creator><creator>Kloc, M</creator><creator>Wyman-Chick, K A</creator><creator>Valkovic, P</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20220101</creationdate><title>Restless legs syndrome in Parkinson's disease: relationship with quality of life and medication</title><author>Minar, M ; Kosutzka, Z ; Danterova, K ; Gmitterova, K ; Straka, I ; Kusnirova, A ; Tosecka, R ; Juricek, R ; Kloc, M ; Wyman-Chick, K A ; Valkovic, P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c329t-d6ba78cdb67c0ac4945d92473a41325c16ffb05e6aa831da8e997b9e1780805a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Dopamine Agonists - adverse effects</topic><topic>Humans</topic><topic>Parkinson Disease - complications</topic><topic>Parkinson Disease - drug therapy</topic><topic>Parkinson Disease - epidemiology</topic><topic>Quality of Life</topic><topic>Restless Legs Syndrome - drug therapy</topic><topic>Restless Legs Syndrome - epidemiology</topic><topic>Surveys and Questionnaires</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Minar, M</creatorcontrib><creatorcontrib>Kosutzka, Z</creatorcontrib><creatorcontrib>Danterova, K</creatorcontrib><creatorcontrib>Gmitterova, K</creatorcontrib><creatorcontrib>Straka, I</creatorcontrib><creatorcontrib>Kusnirova, A</creatorcontrib><creatorcontrib>Tosecka, R</creatorcontrib><creatorcontrib>Juricek, R</creatorcontrib><creatorcontrib>Kloc, M</creatorcontrib><creatorcontrib>Wyman-Chick, K A</creatorcontrib><creatorcontrib>Valkovic, P</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Bratislava Medical Journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Minar, M</au><au>Kosutzka, Z</au><au>Danterova, K</au><au>Gmitterova, K</au><au>Straka, I</au><au>Kusnirova, A</au><au>Tosecka, R</au><au>Juricek, R</au><au>Kloc, M</au><au>Wyman-Chick, K A</au><au>Valkovic, P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Restless legs syndrome in Parkinson's disease: relationship with quality of life and medication</atitle><jtitle>Bratislava Medical Journal</jtitle><addtitle>Bratisl Lek Listy</addtitle><date>2022-01-01</date><risdate>2022</risdate><volume>123</volume><issue>1</issue><spage>55</spage><epage>60</epage><pages>55-60</pages><issn>0006-9248</issn><issn>1336-0345</issn><eissn>1336-0345</eissn><abstract>We aimed to disclose the relationship between restless leg syndrome (RLS) and antiparkinsonian treatment, and its effect on quality of life (QoL) in patients with Parkinson's disease (PD).
Previous studies documented the prevalence of RLS among patients with PD to be higher than in the general population, but conclusions regarding the aetiology and impact were contradictory.
We examined 101 patients with idiopathic PD. All participants completed the five-dimension/five-level-EuroQoL questionnaire (EQ-5D-5L) and the International Restless-Legs-syndrome-study-group rating Scale (IRLS).
The prevalence of RLS was 22.77 %. There were no statistically significant differences in levodopa or dopamine agonists (DA) doses between RLS-positive and negative participants. However, the use of levodopa as the last night-time medication was connected with a higher risk of RLS (OR=2.049, p=0.041). There was significantly lower prevalence of RLS in patients after surgical treatment for PD (p=0.024). Participants with RLS were at a greater risk for sleep disturbances (OR=3.866, p=0.023) and excessive daytime sleepiness (OR=7.202, p<0.001). Greater RLS symptoms were associated with worse QoL (higher IRLS score predicted higher EQ5D5L score, p=0.023).
RLS is prevalent among PD patients and night-time dopaminergic over-excitation with levodopa plays an important role in its pathogenesis. Since the symptoms of RLS are associated with decreased QoL, early accurate diagnosis and appropriate adjustment of dopaminergic therapy can lead to immediate relief from RLS symptoms and to QoL improvement (Tab. 4, Fig. 1, Ref. 34).</abstract><cop>Slovakia</cop><pmid>34967659</pmid><doi>10.4149/BLL_2022_009</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0006-9248 |
| ispartof | Bratislava Medical Journal, 2022-01, Vol.123 (1), p.55-60 |
| issn | 0006-9248 1336-0345 1336-0345 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2615477758 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Dopamine Agonists - adverse effects Humans Parkinson Disease - complications Parkinson Disease - drug therapy Parkinson Disease - epidemiology Quality of Life Restless Legs Syndrome - drug therapy Restless Legs Syndrome - epidemiology Surveys and Questionnaires |
| title | Restless legs syndrome in Parkinson's disease: relationship with quality of life and medication |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T19%3A14%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Restless%20legs%20syndrome%20in%20Parkinson's%20disease:%20relationship%20with%20quality%20of%20life%20and%20medication&rft.jtitle=Bratislava%20Medical%20Journal&rft.au=Minar,%20M&rft.date=2022-01-01&rft.volume=123&rft.issue=1&rft.spage=55&rft.epage=60&rft.pages=55-60&rft.issn=0006-9248&rft.eissn=1336-0345&rft_id=info:doi/10.4149/BLL_2022_009&rft_dat=%3Cproquest_cross%3E2615477758%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2615477758&rft_id=info:pmid/34967659&rfr_iscdi=true |